ArticleBioinformatics (Oxford, England)2011
PathScan: a tool for discerning mutational significance in groups of putative cancer genes.
Article in Bioinformatics (Oxford, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2018Pooled it
- Identifying multigenic modules under selection in the tumor genome.Bioinformatics (Oxford, England) · 2026Article
- IsJournal of oral microbiology · 2025Article
- Identification of cancer driver genes based on hierarchical weak consensus model.Health information science and systems · 2024Article
- Genetic Alterations in Papillary Thyroid Carcinoma With HashimotoFrontiers in oncology · 2022Article
- Clinical and molecular features of sacrum chordoma in Chinese patients.Annals of translational medicine · 2022Article
- Moving pan-cancer studies from basic research toward the clinic.Nature cancer · 2021Review
- Analysis, identification and visualization of subgroups in genomics.Briefings in bioinformatics · 2021Review
- Profiling of 520 Candidate Genes in 50 Surgically Treated Chinese Small Cell Lung Cancer Patients.Frontiers in oncology · 2021Article
- Computational methods for cancer driver discovery: A survey.Theranostics · 2021Review
- ClinVAP: a reporting strategy from variants to therapeutic options.Bioinformatics (Oxford, England) · 2020Article
- PTMsnp: A Web Server for the Identification of Driver Mutations That Affect Protein Post-translational Modification.Frontiers in cell and developmental biology · 2020Article
- Genomic profiling of colorectal cancer with isolated lung metastasis.Cancer cell international · 2020Article
- Article
- Identification of somatic alterations in lipoma using whole exome sequencing.Scientific reports · 2019Article
- Gene Expression Patterns Unveil New Insights in Papillary Thyroid Cancer.Medicina (Kaunas, Lithuania) · 2019Article
- Identification of Common and Subtype-Specific Mutated Sub-Pathways for a Cancer.Frontiers in genetics · 2019Article
- Maftools: efficient and comprehensive analysis of somatic variants in cancer.Genome research · 2018Article
- Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.International journal of cancer · 2018Article
- Identification of Biomarkers Based on Differentially Expressed Genes in Papillary Thyroid Carcinoma.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
motivationThe expansion of cancer genome sequencing continues to stimulate development of analytical tools for inferring relationships between somatic changes and tumor development. Pathway associations are especially consequential, but existing algorithms are demonstrably inadequate.
methodsHere, we propose the PathScan significance test for the scenario where pathway mutations collectively contribute to tumor development. Its design addresses two aspects that established methods neglect. First, we account for variations in gene length and the consequent differences in their mutation probabilities under the standard null hypothesis of random mutation. The associated spike in computational effort is mitigated by accurate convolution-based approximation. Second, we combine individual probabilities into a multiple-sample value using Fisher-Lancaster theory, thereby improving differentiation between a few highly mutated genes and many genes having only a few mutations apiece. We investigate accuracy, computational effort and power, reporting acceptable performance for each.
resultsAs an example calculation, we re-analyze KEGG-based lung adenocarcinoma pathway mutations from the Tumor Sequencing Project. Our test recapitulates the most significant pathways and finds that others for which the original test battery was inconclusive are not actually significant. It also identifies the focal adhesion pathway as being significantly mutated, a finding consistent with earlier studies. We also expand this analysis to other databases: Reactome, BioCarta, Pfam, PID and SMART, finding additional hits in ErbB and EPHA signaling pathways and regulation of telomerase. All have implications and plausible mechanistic roles in cancer. Finally, we discuss aspects of extending the method to integrate gene-specific background rates and other types of genetic anomalies. AVAILABILITY: PathScan is implemented in Perl and is available from the Genome Institute at: http://genome.wustl.edu/software/pathscan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.